Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.59 |
| ▸ | TYMP | P19971 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198387 | 0.90 | TK2 (0.55) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL18503446 | 0.88 | LMNA (0.47) | TK2TYMPLMNA | |
| SCHEMBL9556674 | 0.86 | TK2 (0.57) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL14928930 | 0.85 | TK2 (0.53) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL14928922 | 0.85 | TK2 (0.53) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL7781617 | 0.85 | TK2 (0.61) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL18503443 | 0.83 | SLC28A1 (0.57) | LMNA | |
| SCHEMBL18503431 | 0.82 | POLB (0.55) | POLB | |
| SCHEMBL20154860 | 0.81 | LMNA (0.56) | TK2TYMPLMNAALBBLM | |
| SCHEMBL13205001 | 0.81 | LMNA (0.59) | TK2TYMPALDH1A1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | TK2 83/4885TYMP 108/4885ALDH1A1 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.